ישראל - עברית - Ministry of Health

csl behring ltd., israel - albumin human - תמיסה לאינפוזיה - albumin human 200 mg/ml - albumin - albumin - hypoalbuminemia (liver cirrhosis nephrosis) toxic processes ( pregnancy toxicosis, hyperbilirubinemia ) ,volume substitution therapy.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - immunoglobulins, normal human - תמיסה להזרקה - immunoglobulins, normal human 160 mg/ml - immunoglobulins, normal human, for extravascular adm. - immunoglobulins, normal human, for extravascular adm. - substitution in - primary antibody deficiency syndromes resulting from defective antibody synthesis. - protracted transitory hypogammaglobulinaemia especially in premature infants .prophylaxis of hepatitis a- before exposure- within 2 weeks after exposure

ישראל - עברית - Ministry of Health

csl behring ltd., israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 100 g/l - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - 1. replacement therapy in- primary immunodeficiency syndromes such as:- congenital agammaglobulinaemia and hypogammaglobulinaemia- common variable immunodeficiency- severe combined immunodeficiency- wiskott-aldrich syndrome- myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections-children with congenital aids and recurrent infections2. immunomodulation- immune thrombocytopenic purpura (itp) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count-guillain-barr? syndrome- kawasaki disease3. allogeneic bone marrow transplantation

ישראל - עברית - Ministry of Health

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

ישראל - עברית - Ministry of Health

csl behring ltd., israel - human-rabies immunoglobulin - תמיסה להזרקה - human-rabies immunoglobulin 150 iu/ml - rabies immunoglobulin - rabies immunoglobulin - prophylaxis of rabies.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - albutrepenonacog alfa - אבקה וממס להכנת תמיסה להזרקה - albutrepenonacog alfa 1000 iu - coagulation factor ix

ישראל - עברית - Ministry of Health

csl behring ltd., israel - albutrepenonacog alfa - אבקה וממס להכנת תמיסה להזרקה - albutrepenonacog alfa 2000 iu - coagulation factor ix

ישראל - עברית - Ministry of Health

csl behring ltd., israel - albutrepenonacog alfa - אבקה וממס להכנת תמיסה להזרקה - albutrepenonacog alfa 250 iu - coagulation factor ix

ישראל - עברית - Ministry of Health

csl behring ltd., israel - albutrepenonacog alfa - אבקה וממס להכנת תמיסה להזרקה - albutrepenonacog alfa 500 iu - coagulation factor ix

ישראל - עברית - Ministry of Health

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 400 - 960 iu; coagulation factor vii (human) 200 - 500 iu; coagulation factor ix (human- rfixfc) 400 - 620 iu; coagulation factor x (human) 440 - 1200 iu; protein c 300 - 900 iu; protein s antigen 240 - 760 iu - coagulation factor ix, ii, vii and x in combination